Sick Cells worked in collaboration with the University of Southern California Hematology Utilization Group Studies (USC HUGS) and the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at University of Washington School of Pharmacy, to identify and assess core elements of value to be incorporated into SCD research measures.
Sick Cells collaborated with the University of Pittsburgh to study the barriers to accessing disease-modifying treatments.
Sick Cells collaborated with QC Medica and Vertex Pharmaceuticals to survey individuals living with sickle cell disease (SCD) on the impacts of the disease on quality of life and health quality.
Pfizer worked with Sick Cells to develop a survey to understand how much different features of potential sickle cell treatments matter to people with sickle cell disease and caregivers of people with sickle cell disease.
